secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2022-04-18T23:59:59+00:00
Accession:  0001193125-22-108155
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte enters manufacturing pact with Lonza for pneumococcal vaccine
---------------------------------------------------------------------

- Master Services Agreement effective March 22, 2022 for clinical manufacturing of Vaxcyte's PCV.
- Initial term of five years; either party may terminate for material breach, insolvency, or convenience.
- Vaxcyte owns IP directly derivative of its product; Lonza owns generally applicable IP or improvements to Lonza background.
- No financial terms disclosed; Lonza paid for services, pass-through costs, and a procurement fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312522108155/0001193125-22-108155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312522108155/d292140d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-108155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer